Bioverativ Inc (BIVV.OQ)
16 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|55||2017||Independent Chairman of the Board|
|54||2016||Chief Executive Officer, Director|
|51||2016||Chief Financial Officer, Executive Vice President, Treasurer|
|53||2016||Executive Vice President, Chief Global Therapeutic Operations Officer|
|51||2017||Executive Vice President, Chief Human Resources and Corporate Communications Officer|
- Oxford BioMedica wins second $100 million gene therapy contract
- Oxford BioMedica wins second $100 mln gene therapy contract
- BRIEF-Bioverativ Q4 Revenue Rose 28.3 Percent To $328.7 Million
- BRIEF-Sanofi Commences Tender Offer For Acquisition Of Bioverativ
- Sanofi's return to profit growth this year slower than hoped